DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) August 13, 2019 • 9:00 AM EDT
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) July 31, 2019 • 8:00 AM EDT
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme July 24, 2019 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019 June 25, 2019 • 5:28 PM EDT
Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering June 11, 2019 • 5:30 AM EDT
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting June 3, 2019 • 8:45 AM EDT